THE US Food and Drug Administration has approved the first generic versions of EpiPen and EpiPen Jr auto-injector for the emergency treatment of allergic reactions, including anaphylaxis.
Teva Pharmaceuticals USA has gained approval to market its generic epinephrine auto-injector in 0.3mg and 0.15mg strengths, with FDA Commissioner Scott Gottlieb saying the move means patients living with severe allergies will have a lower-cost option, as well as another approved product to help protect against shortages.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Aug 18
